Cargando…

Ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Public Institution(s). Main funding source(s): National Institute of Health Research St George's, University of London BACKGROUND: SCN5A-E1784K (c.5350G>A) is the most common variant associated with the LQT3 long QT syndrome (LQTS) and Bruga...

Descripción completa

Detalles Bibliográficos
Autores principales: Wijeyeratne, Y, Tanck, M W, Mckeown, P P, Probst, V, Crotti, L, Page, S, Galvin, J, Petzer, E, Horie, M, Roden, D, Veltmann, C, Makita, N, Aiba, T, Ackerman, M J, Behr, E R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207071/
http://dx.doi.org/10.1093/europace/euad122.280
_version_ 1785046368507658240
author Wijeyeratne, Y
Tanck, M W
Mckeown, P P
Probst, V
Crotti, L
Page, S
Galvin, J
Petzer, E
Horie, M
Roden, D
Veltmann, C
Makita, N
Aiba, T
Ackerman, M J
Behr, E R
author_facet Wijeyeratne, Y
Tanck, M W
Mckeown, P P
Probst, V
Crotti, L
Page, S
Galvin, J
Petzer, E
Horie, M
Roden, D
Veltmann, C
Makita, N
Aiba, T
Ackerman, M J
Behr, E R
author_sort Wijeyeratne, Y
collection PubMed
description FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Public Institution(s). Main funding source(s): National Institute of Health Research St George's, University of London BACKGROUND: SCN5A-E1784K (c.5350G>A) is the most common variant associated with the LQT3 long QT syndrome (LQTS) and Brugada syndrome (BrS). It exhibits incomplete penetrance and can manifest variably as a mixed clinical phenotype of LQTS, BrS and/or conduction disorders (1-4). This presents a challenge for risk stratification and optimal management. We aimed to describe the clinical characteristics and risk markers in a large, well characterised international cohort of SCN5A-E1784K subjects and identify demographic and/or ECG parameters associated with event free survival. METHODS: Comprehensive clinical data, including initial presentation and follow-up data, were collected from SCN5A-E1784K subjects. Outcome ‘events’ included sudden death, aborted cardiac arrest, and documented VF or VT or arrhythmic syncope. ‘Lethal events’ included sudden death, aborted cardiac arrest or documented VF or VT. Associations between clinical characteristics and event free survival were investigated using Cox proportional hazard regression models. RESULTS: SCN5A-E1784K subjects (n=231) were recruited from 16 centres. Median follow up was 24.9 years (15.2 - 43.3) and 45 individuals (19%) experienced an event. Lethal events were observed in 14 subjects (6%). Figure 1 shows event (A) and lethal event (B) free survival in SCN5A-E1784K subjects. Higher QRS duration (corrected for age) was associated with shorter event-free interval. QRS duration was the only characteristic associated with increased risk with a hazard ratio (HR) of 1.04 or 1.05 per ms for events and lethal events, respectively. The observed survival for events and lethal events for QRS tertiles are shown in Figure 2. Discussion Ventricular myocardial conduction, as evidenced by QRS duration, appears to play a role in the risk of arrhythmic events in patients with SCN5A-E1784K. Corrected QT interval and BrS phenotype were, however, not associated with risk. This provides an important opportunity for the personalisation of risk stratification of these patients, whose management can otherwise be very challenging. Figures [Figure: see text] [Figure: see text]
format Online
Article
Text
id pubmed-10207071
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102070712023-05-25 Ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease Wijeyeratne, Y Tanck, M W Mckeown, P P Probst, V Crotti, L Page, S Galvin, J Petzer, E Horie, M Roden, D Veltmann, C Makita, N Aiba, T Ackerman, M J Behr, E R Europace 13.2 - Epidemiology, Prognosis, Outcome FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Public Institution(s). Main funding source(s): National Institute of Health Research St George's, University of London BACKGROUND: SCN5A-E1784K (c.5350G>A) is the most common variant associated with the LQT3 long QT syndrome (LQTS) and Brugada syndrome (BrS). It exhibits incomplete penetrance and can manifest variably as a mixed clinical phenotype of LQTS, BrS and/or conduction disorders (1-4). This presents a challenge for risk stratification and optimal management. We aimed to describe the clinical characteristics and risk markers in a large, well characterised international cohort of SCN5A-E1784K subjects and identify demographic and/or ECG parameters associated with event free survival. METHODS: Comprehensive clinical data, including initial presentation and follow-up data, were collected from SCN5A-E1784K subjects. Outcome ‘events’ included sudden death, aborted cardiac arrest, and documented VF or VT or arrhythmic syncope. ‘Lethal events’ included sudden death, aborted cardiac arrest or documented VF or VT. Associations between clinical characteristics and event free survival were investigated using Cox proportional hazard regression models. RESULTS: SCN5A-E1784K subjects (n=231) were recruited from 16 centres. Median follow up was 24.9 years (15.2 - 43.3) and 45 individuals (19%) experienced an event. Lethal events were observed in 14 subjects (6%). Figure 1 shows event (A) and lethal event (B) free survival in SCN5A-E1784K subjects. Higher QRS duration (corrected for age) was associated with shorter event-free interval. QRS duration was the only characteristic associated with increased risk with a hazard ratio (HR) of 1.04 or 1.05 per ms for events and lethal events, respectively. The observed survival for events and lethal events for QRS tertiles are shown in Figure 2. Discussion Ventricular myocardial conduction, as evidenced by QRS duration, appears to play a role in the risk of arrhythmic events in patients with SCN5A-E1784K. Corrected QT interval and BrS phenotype were, however, not associated with risk. This provides an important opportunity for the personalisation of risk stratification of these patients, whose management can otherwise be very challenging. Figures [Figure: see text] [Figure: see text] Oxford University Press 2023-05-24 /pmc/articles/PMC10207071/ http://dx.doi.org/10.1093/europace/euad122.280 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle 13.2 - Epidemiology, Prognosis, Outcome
Wijeyeratne, Y
Tanck, M W
Mckeown, P P
Probst, V
Crotti, L
Page, S
Galvin, J
Petzer, E
Horie, M
Roden, D
Veltmann, C
Makita, N
Aiba, T
Ackerman, M J
Behr, E R
Ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease
title Ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease
title_full Ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease
title_fullStr Ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease
title_full_unstemmed Ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease
title_short Ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease
title_sort ventricular conduction is a marker for arrhythmic risk in overlap sodium channel disease
topic 13.2 - Epidemiology, Prognosis, Outcome
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207071/
http://dx.doi.org/10.1093/europace/euad122.280
work_keys_str_mv AT wijeyeratney ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease
AT tanckmw ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease
AT mckeownpp ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease
AT probstv ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease
AT crottil ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease
AT pages ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease
AT galvinj ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease
AT petzere ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease
AT horiem ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease
AT rodend ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease
AT veltmannc ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease
AT makitan ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease
AT aibat ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease
AT ackermanmj ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease
AT behrer ventricularconductionisamarkerforarrhythmicriskinoverlapsodiumchanneldisease